Anastrozole shows promise for early breast cancerBMJ 2002; 324 doi: http://dx.doi.org/10.1136/bmj.324.7353.1539 (Published 29 June 2002) Cite this as: BMJ 2002;324:1539
- Susan Mayor
The aromatase inhibitor anastrozole (Arimidex) has shown similar disease-free survival but fewer side effects than the established treatment, tamoxifen, in a major trial of postmenopausal women with hormone sensitive, early breast cancer (Lancet 2002;359:2131-9).
First results from the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial showed a small but non-significant increase in disease-free survival at three years with anastrozole (89.4% compared with 87.4% with tamoxifen (hazard ratio 0.83; 95% confidence interval …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial